Low insulin-like growth factor 1 is associated with low high-density lipoprotein cholesterol and metabolic syndrome in Chinese nondiabetic obese children and adolescents: a cross-sectional study by unknown
RESEARCH Open Access
Low insulin-like growth factor 1 is
associated with low high-density
lipoprotein cholesterol and metabolic
syndrome in Chinese nondiabetic
obese children and adolescents:
a cross-sectional study
Shuang Liang, Yanyan Hu, Caihong Liu, Jianhong Qi and Guimei Li*
Abstract
Background: Low serum high-density lipoprotein cholesterol (HDL-C) is an independent risk factor for developing
cardiovascular disease. Insulin-like growth factor 1(IGF-1) levels have been proven to be positively associated with
HDL-C, but few studies were based on the dataset of children or adolescents. The aim of this study is to investigate
the relationship among IGF-1, HDL-C and the metabolic syndrome in Chinese nondiabetic obese children and
adolescents.
Methods: As a cross-sectional study, this study includes 120 obese Chinese children and adolescents and 120
healthy ones. The obese subjects were divided into two groups based on using 1.03 mmol/L as a threshold value
for HDL-C. Clinical examination and laboratory examinations were assessed for all participants.
Results: Obese subjects had significantly lower IGF-1SDS and higher Height SDS than those in the control group.
Among 120 obese children and adolescents, 22 (18.3 %) subjects had an HDL-C level <1.03 mmol/L. IGF-1SDS was
significantly lower (P = 0.001) in obese subjects with low HDL-C. According to the results of multivariate logistic
regression analysis, IGF-1 SDS is significantly associated with low HDL-C(OR 0.518, 95 % CI 0.292–0.916; P = 0.024),
after being adjusted for age, gender, pubertal status, BMI SDS, SBP, DBP, HOMR-IR, total cholesterol, low density
lipoprotein-cholesterol, triglycerides, ALT and uric acid. In addition, IGF-1 SDS is significantly correlated with the
level of serum HDL-C in study population (r = 0.19, P = 0.003). Based on logistic regression analysis with adjustment
for age, gender and pubertal status, the increased IGF-1 SDS was associated with a decreased probability of
metabolic syndrome (OR 0.555, 95 % CI 0.385–0.801; P = 0.002) and hypertriglyceridemia (OR 0.582, 95 % CI 0.395–0.
856; P = 0.006), but no significant correlation with hypertension.
Conclusion: Obese children had lower IGF-1SDS and taller stature compared with the control group.
Low levels of IGF-1 SDS were associated with low levels of HDL-C in chinese nondiabetic obese children and
adolescents, independent of insulin resistance, as well as other traditional cardiovascular disease risk markers.
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Background
The prevalence and severity of childhood obesity are in-
creasing rapidly, and they have reached epidemic levels
globally. In developed countries, the prevalence of over-
weight and obesity has been reported to be 23.8 % of
boys and 22.6 % of girls in 2013 [1]. A previous survey
conducted by Chinese scholars showed that the preva-
lence of obesity was 49.1 % for boys and 30.8 % for girls
in the center of Shanghai city [2]. The ever-growing
number of obesity children will cause lots of serious
issues since obesity is recognized as a central feature
of the metabolic syndrome, and it is always associated
with insulin resistance, hypertension, dyslipidaemia,
hyperglycemia and cardiovascular disease [3]. Low
serum high-density lipoprotein cholesterol (HDL-C),
which is identified as an independent risk factor for
developing cardiovascular disease is also linked with
obesity.
As an important mediator of growth hormone (GH)
secretion, Insulin-like growth factor 1 (IGF-1) is primar-
ily synthesized from the liver, which plays a key role in
normal growth and development. Nowadays, increasing
evidences suggest that a lower IGF-1 level is associated
with obesity [4], insulin resistance [5], metabolic syn-
drome [6, 7], impaired glucose tolerance [8], nonalco-
holic fatty liver disease (NAFLD) [9] and cardiovascular
disease [10]. Similarly, HDL-C and IGF-1 share many
common features. Both of them are secreted partially
from the liver, and HDL-C is also linked to the same clus-
ter of cardio-metabolic disorders. Moreover, the positive
correlation between IGF-1 and HDL-C had been proposed
in some studies [11–14]. However, previous studies relat-
ing to the relationship between HDL-C and IGF-1 are still
some topical and controversial. Furthermore, this relation-
ship didn’t focus on the samples of children and adoles-
cents, especially those of obese group. Therefore, in this
present study, we aimed to investigate the association be-
tween IGF-1 and HDL-C, metabolic syndrome in nondia-
betic obese children and adolescents.
Methods
Subjects
This retrospective cross-sectional study was carried out
at the Department of Pediatrics of Shandong Provincial
Hospital affiliated to Shandong University. We investi-
gated a group of obese subjects and a group of healthy
controls respectively. A total of 120 obese children and
adolescents (age ranging from 10 to 16) was conducted
from July of 2011 to November of 2015. The diagnosis
of obesity is those children whose body mass index
(BMI) are above the 95th percentile with age and sex
adjustment, based on the national reference data [15].
The exclusion criteria for our study were: 1) children
who had ever had renal disease, liver failure, cancer, and
other systemic severe diseases; 2) children with hypo-
thalamus diseases, pituitary diseases, thyroid dysfunc-
tion, diabetes mellitus, chromosome abnormalities or all
sorts of syndromes; 3) the obese children who had been
smokers, and those who ever had chronic alcohol intake,
and used drugs which may influence lipid metabolism,
blood pressure, liver function, insulin action, glucose
and weight. Control subjects which include 120 chil-
dren and adolescents, were recruited from a population
of non-obese healthy children and adolescents. The
obesity group and control group were matched on age,
pubertal status and gender. The study was approved by
the Ethics Committee of the Shandong Provincial
Hospital Affiliated to Shandong University. Written in-
formed consents had been signed by all participants’
parents.
Anthropomorphic measurements
Anthropometric measurements, including measure-
ments of weight, height, systolic blood pressure (SBP),
diastolic blood pressure (DBP), and pubertal staging
were assessed for each participant. Body weight was
measured to the nearest 0.1 kg for all subjects wearing
light clothing and no shoes. The degree of obesity was
calculated as body mass index (BMI) (kg/m2). To
minimize the confounding effects of age and sex, we
transformed BMI into BMI standard deviation scores
(BMI SDS) based on normative values for Chinese chil-
dren [15]. Height was measured in the morning, and
there was also nearest 0.1 cm errors. Height was
expressed as height standard deviation scores (Height
SDS) based on normative values for Chinese children
[16]. An average of three blood pressure measurements
was taken while the subjects were seated after 5 min’
rest. The stage of puberty was assessed according to
Tanner criteria [17]. Boys with pubic hair and gonadal
stage 1, and girls with pubic hair and breast stage 1 were
considered as prepuberty [18, 19].
Laboratory measurements
Fasting blood samples were obtained for all participants
after an overnight fast to measure serum IGF-1 level and
other metabolic parameters.
Serum concentration of IGF-1 was estimated based on
chemiluminescence assay (IMMULITE 2000, Siemens
Health care Diagnostics, USA). Intra-assay and inter-
assay coefficient of variation declared by the manufac-
turer was 2.5–7.6 % for IGF-1 measurement. IGF-1 was
represented as IGF-1 standard deviation scores (IGF-1
SDS), based on age and sex normal range of the popula-
tion by past researches [20]. Total cholesterol (TC),
HDL-C, low density lipoprotein-cholesterol(LDL-C), tri-
glycerides(TG), fasting plasma glucose (FPG), alanine
aminotransferase (ALT), and uric acid (UA) were
Liang et al. Lipids in Health and Disease  (2016) 15:112 Page 2 of 7
determined using an Auto Biochemical Analyzer (AU5400,
Beckman Coulter, Tokyo, Japan). Fasting insulin were
assayed using a chemiluminescent immunometric assays
(CobasE170, Roche Diagnostics, Mannheim, Germany).
The intra-assay and inter-assay coefficients of variation
were <7.0 % in these assays. Estimates of insulin resistance
were calculated using the following formula of homeostasis
model assessment-insulin resistance (HOMA-IR) = insulin
(uIU/ml) × glucose (mmol/l))/22.5 [21]. An oral glucose
tolerance test (OGTT) was performed with 1.75 g of
glucose kg of weight (to a maximum of 75 g) in fasting
glucose ≥ 5.6 mmol/L subjects in order to rule out diabetes
mellitus.
Definition
The metabolic syndrome was defined as the presence of
any three or more of the following five constituent risks
according to the criteria of International Diabetes Feder-
ation [22]: 1) abdominal obesity. 2) low HDL-C. 3)
hypertriglyceridemia. 4) hypertension. 5) impaired
fasting glucose. Low HDL-C was defined as HDL-C
levels <1.03 mmol/L. Hypertriglyceridemia was de-
fined as triglyceride ≥ 1.7 mmol/L. Hypertension was
defined as SBP ≥ 130 mmHg or DBP ≥ 85 mmHg.
Impaired fasting glucose was defined as fasting glu-
cose ≥ 5.6 mmol/L.
Statistical analysis
Normally distributed variables were expressed as means
± standard deviation (SD). Skewed distributed variables
were natural log transformed, and were expressed as
mean ± SD. Skewed distributed variables were expressed
as median (interquartile range) since they can not be
transformed to normal distribution. Groups were com-
pared using the Student’s t tests or Mann–Whitney U
test. Categorical variables were compared by chi square
test. The relationships among serum IGF-1 SDS, clinical
and metabolic variables were evaluated with Pearson’s
correlation analysis or Spearman correlation analysis. A
multivariable logistic regression analysis was used to de-
termine the association between IGF-1 SDS and the low
HDL-C(<1.03 mmol/L) after adjustment for anthropo-
metric, metabolic variables. In multiple logistic models,
only HOMA-IR representing fasting glucose and insulin
respectively, were used to avoid collinearity. Logistic regres-
sion analysis was also applied to demonstrate the associ-
ation among the metabolic syndrome, hypertriglyceridemia,
hypertension and IGF-1SDS. The presence of the metabolic
syndrome, hypertriglyceridemia and hypertension was used
as a dependent variable and IGF-1SDS as an independent
variable after adjustment for age, gender and pubertal
status. A P value <0.05 was considered statistically signifi-
cant. Statistical analyses were all carried out using SPSS
version 17.0 (SPSS Inc. Chicago, USA).
Results
The characteristics of the study population are shown in
Table 1. Gender, age, pubertal status and fasting glucose
were similar in obesity group and control group. In the
obese group, significant percentages of clinical and
metabolic alterations were observed. Notably, The obese
group had significantly lower IGF-1 SDS (P < 0.001),
HDL-C (P < 0.001) than the control group. In contrast,
the obese group showed significantly higher levels of
Height SDS, SBP, DBP, BMI SDS, HOMA-IR than the
control group, The levels of total cholesterol, low density
lipoprotein-cholesterol, triglycerides, uric acid, ALT also
were significantly higher in the obese group than those
in the control group.
A total of 120 obese participants with a mean age of
12.09 ± 1.35 years old were included in the study.
Among the 120 obese participants, 101 (84.2 %) children
were male. The majority of children were prepubertal
(81, 67.5 %). Low levels of HDL-C were observed in 22
of 120 obese participants (18.3 %). 26 subjects had a tri-
glyceride ≥ 1.7 mmol/L(21.7 %, 26/120), while Hyperten-
sion was observed in 39.2 % (47/120) of assessed
individuals and metabolic syndrome in 28.3 % (34/120)
of them. In addition, we observed 18 of 120 obese par-
ticipants (15 %), which has impaired fasting glucose after
excluding type 1 and 2 diabetes mellitus.
Obese children were further divided into two groups ac-
cording to HDL-C level. The characteristics of the two
groups are shown in Table 2. IGF-1 SDS were significantly






Age (yr) 12.09(1.35) 11.63(2.27) 0.054
Male/Female, (n) 101/19 88/32 0.058a
Prepuberty/Puberty,(n) 81/39 76/44 0.587a
IGF-1SDS −0.33(1.35) 0.66(1.23) <0.001*
SBP (mmHg) 121.08(12.84) 106.69(9.7) <0.001*
DBP (mmHg) 78.79(10.41) 70.69(7.61) <0.001*
BMISDS 2.71(0.78) 0.04(0.77) <0.001*
Height SDS 1.03(0.46–1.93) −0.26(−0.71–0.41) <0.001*a
HOMA-IR 6.35(3.8) 2.67(1.53) <0.001*
FPG (mmol/L) 5.08(0.44) 5.07(0.42) 0.894
TC (mmol/L) 4.24(3.78–4.84) 4.01(3.64–4.37) <0.001*a
TG (mmol/L) 1.4(0.87) 0.79(0.32) <0.001*
HDL-C (mmol/L) 1.23(0.29) 1.53(0.33) <0.001*
LDL-C (mmol/L) 2.53(0.61) 2.11(0.52) <0.001*
UA(μmol/L) 386.68(96.18) 298.29(69.42) <0.001*
ALT((U/L)) 25.00(18.00–40.00) 13.50(11.00–17.00) <0.001*a
SBP, HOMA-IR, triglycerides, uric acid were log transformed for statistical ana-
lysis, but values in the table represent a back transformation to the original
* P < 0.05, aMann-Whitney U test or the chi-square test
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lower (P = 0.001) in obese subjects with low HDL-C group
than in subjects with HDL-C ≥1.03 mmol/L, whereas
triglycerides were higher in obese children with HDL-
C < 1.03 mmol/L than obese children with HDL-C
≥1.03 mmol/L. No difference existed in the age, gen-
der, pubertal status, Height SDS, SBP, DBP, BMI
SDS, HOMA-IR, fasting glucose, total cholesterol, low
density lipoprotein-cholesterol, uric acid and ALT be-
tween the two groups.
Through multiple logistic regression analysis, we ob-
served that in the final model, after adjusting for age,
gender, pubertal status, BMI SDS, SBP, DBP, HOMR-IR,
total cholesterol, low density lipoprotein-cholesterol,
triglycerides, ALT, uric acid. Notably, the increased IGF-
1SDS was associated with a decreased probability of low
HDL-C (OR 0.518, 95 % CI 0.292–0.916; P = 0.024).
We performed a bivariate correlation analysis to explicit
the relationship between IGF-1SDS and cardiometabolic
variables in study population (Table 3). IGF-1 SDS was
significantly correlated with HDL-C(r = 0.19, P = 0.003),
BMI SDS(r = −0.25, P < 0.001), SBP (r = −0.134, P = 0.038),
DBP (r = −0.197, P = 0.002), total cholesterol (r = −0.157,
P = 0.015), low density lipoprotein-cholesterol (r =
−0.182, P = 0.005), triglycerides (r = −0.179, P = 0.006)
and ALT (r = −0.266, P < 0.001). But no correlation
was observed with age, HOMA-IR, fasting glucose
and uric acid. Notably, correlation between IGF-1
SDS and HDL-C is also significant.
Logistic regression analysis was also applied to
study the association among IGF-1SDS and the meta-
bolic syndrome, hypertriglyceridemia and hyperten-
sion, adjusted for gender and pubertal status. The
increased IGF-1 SDS was associated with a decreased
probability of metabolic syndrome (OR 0.555, 95 %
CI 0.385–0.801; P = 0.002) and hypertriglyceridemia
(OR 0.582, 95 % CI 0.395–0.856; P = 0.006), but with
no significant correlation with hypertension (OR
0.765, 95 % CI 0.567–1.031; P = 0.079).
Discussion
In this study, we found that low IGF-1 SDS is positively
correlated with low HDL-C levels in nondiabetic obese
children and adolescents. More importantly, the positive
relationship remains significant after controlling several
confounders.
Obesity represents a major worldwide health problem,
and it is always associated with the incidence of multiple
comorbidities. In present study, in accordance with pre-
vious reports [3], we found that obese children had sig-
nificantly lower HDL-C, higher levels of SBP, DBP, BMI
SDS, HOMA-IR, uric acid, ALT and an adverse lipid
profile compared with the control group.
Apart from obesity-related co-morbidities, obesity is
also associated with endocrine perturbations. The influ-
ences of obesity on the GH-IGF-1 axis and growth have
been recognized. There are lots of evidences to suggest
that obesity is associated with the reduced stimulated
GH release [23, 24] as well as the endogenous GH secre-
tion [25]. This GH deficiency associated with obesity is
relative and with weight loss GH secretion is fully re-
versed [24]. But unlike the unequivocal effects of
Table 2 Clinical and laboratory characteristics in the two
groups of subjects using1.03 mmol/L as a threshold value
for HDL-C





Age (yr) 12.1(1.13) 12.09(1.4) 0.992




IGF-1SDS −1.19(1.4) −0.14(1.27) 0.001*
SBP (mmHg) 121.14(12.43) 121.07(13) 0.963
DBP (mmHg) 80.05(9.37) 78.51(10.65) 0.534
Height SDS 1.18(0.67–1.83) 1.02(0.3–1.97) 0.722a
BMISDS 2.85(0.82) 2.68(0.77) 0.34
HOMA-IR 6.37(4.05) 6.34(3.77) 0.955
FPG (mmol/L) 5.08(0.47) 5.08(0.43) 0.989
TC (mmol/L) 4.12(0.76) 4.46(0.93) 0.105
TG (mmol/L) 2.22(1.47) 1.22(0.53) <0.001*
LDL-C (mmol/L) 2.43(0.47) 2.55(0.63) 0.393
UA(μmol/L) 399.32(95.85) 383.85(96.52) 0.491
ALT((U/L)) 23.5(19.75–37.25) 26.00(17.75–40.00) 0.807a
SBP, HOMA-IR, total cholesterol, triglycerides, uric acid were log transformed
for statistical analysis, but values in the table represent a back transformation
to the original
* P < 0.05, aMann-Whitney U test or the chi-square test
Table 3 Bivariate correlation analysis between IGF-1 SDS and
cardiometabolic variables in study population
Variable r p
Age (yr) 0.112 0.084
SBP (mmHg) −0.134 0.038*
DBP (mmHg) −0.197 0.002*
BMI SDS −0.25 <0.001*
HOMA-IR −0.07 0.279
TC (mmol/L) −0.157 0.015*
HDL-C (mmol/L) 0.19 0.003*
LDL-C (mmol/L) −0.182 0.005*
TG (mmol/L) −0.179 0.006*
UA(μmol/L) 0 0.999
FPG (mmol/L) 0.107 0.099
ALT((U/L)) −0.266 <0.001*
* P < 0.05
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significantly lower GH observed in patients with
obesity, there are some controversies about the rela-
tionship between obesity and IGF-1. Reduced IGF-1 [26,
27], normal [28] or high [29] IGF-1 in obese subjects have
been reported previously. Accordingly, we futher assessed
the relationship between IGF-1SDS and obesity, and our
study showed that the obese subjects had lower IGF-1
SDS compaed with control group. The result is consistent
with those of a previously epidemiological study based on
3328 subjects (aged 19–72 years) which reported a similar
negative correlation between IGF-1 and obesity-related
anthropometric markers in both men and women [26].
Another study based on a small sample dataset also
showed that obese adolescent had lower total IGF-1 values
comparing with lean adolescent subjects [27]. The plaus-
ible reasons for these differences of previous studies are
that: (1) we used the IGF-1SDS as a proxy of IGF-1; (2)
the different samples may creates different results due to
heterogeneity.
Interestingly, despite low GH secretion and the abnor-
malities in the peripheral GH-IGF system in obese chil-
dren, a normal or tall stature is usually observed [30].
Several studies have shown that obese children have
higher height velocity and taller stature than non-obese
children during the prepubertal years, while similar final
heights were usually observed that between obese and
nonobese children [31, 32]. Our study is mainly based
on a sample of prepuberty population and the results of
this study showed that obese group had higher height
SDS compared with control group which is also consist-
ent with those of previous studies. The underlying
mechanisms in this paradoxical combination of the ab-
normalities GH-IGF axis and tall stature remain un-
known. Severalmechanisms such as increased leptin [33]
and insulin [30], increased amount of free-IGF-1 [27],
upregulation of GH receptors [34] have been suggested.
In this study, we provided evidences that lower IGF-1
is positively associated with low HDL-C (HDL-C <
1.03 mmol/L) in Chinese nondiabetic obese children and
adolescents. First, patients with lower HDL-C had lower
IGF-1 SDS. Second, IGF-1 SDS was significantly corre-
lated with serum HDL-C level. Third, logistic regression
analysis further showed that lower IGF-1SDS signifi-
cantly contributed to the risk of low HDL-C. Decreased
IGF-1 and HDL-C levels have been reported to be asso-
ciated with insulin resistance [5, 35–37]. Our results
showed that decreased levels of IGF-1SDS in obese chil-
dren and adolescents were associated with low HDL-C,
independent of insulin resistance, as well as other trad-
itional cardiovascular disease risk markers. Causal rela-
tionship between HDL-C and IGF-1 levels was not
established in this cross sectional series. However, we
speculate that IGF-1 might exert some direct or indirect
effects on HDL-C metabolism.
The exact mechanisms of the relationship between
IGF-1 and HDL-C in obesity are not fully understood at
present. The possible reasons might be listed as follow-
ing: 1) it is easy to explain and prove that IGF-1 may in-
fluence HDL-C, at least partially by improving the
insulin sensitivity [38]. IGF-1 shares structural homology
and downstream pathways with insulin. Low plasma
IGF-1 is associated with reduced insulin sensitivity and
increased insulin resistance, which had been showed in
clinical studies [35, 39]. Insulin resistance was consid-
ered to affect HDL-C metabolism and result in lower
HDL-C [40, 41]. 2) Another possible explanations for
the association between IGF-1 and HDL-C are driven by
GH. Since it is known that IGF-1 serves as a proxy for
the pulsatile GH secretion. Basal and peak stimulated
GH levels were positively associated with HDL-C in sev-
eral research [42–44], and GH treatment in some studies
had been shown to be correlated with a higher level of
HDL-C [45, 46]. It supports that IGF-1 is correlated with
modulating serum HDL concentration. 3)IGF-1 inhibits
expression of hepatic scavenger receptor of class BI
(SRB1) on the surface of liver Hep2 B cells, leading to a
reduction of HDL reverse transport and an increased
circulating HDL-C concentration [47].
Our study highlights the importance of IGF-1 to regu-
late HDL-C. As the component of metabolic syndrome,
low HDL-C may be partially accounted for the association
between IGF-1 and risk of metabolic syndrome. Several
studies had suggested that IGF-1 had robust negative rela-
tionships with metabolic syndrome and its components
[6, 12, 48–51]. Saydah. et al.[48] and Parekh. et al. [49]
noted that IGF-1 concentrations were negatively corre-
lated with metabolic syndrome as well as its individual
components among NHANES III participants. In another
study among patients with impaired glucose tolerance and
subjects with and without diabetes, low plasma IGF-1
concentrations were significantly associated with the pres-
ence of metabolic syndrome and were inversely associated
with a number of individual metabolic syndrome compo-
nents [12]. However, some other clinical reports showed
some inconsistent results regarding the relationship be-
tween IGF-1 with metabolic syndrome [52] and its com-
ponents [53]. A possible reason for this discrepancy might
be that different studies were based on the different char-
acteristics of study groups. In Chinese nondiabetic obese
children and adolescents, we observed that the association
between low IGF-1 SDS and metabolic syndrome was
independent of age, gender and pubertal status. We
further demonstrated low IGF-1 SDS is in negative correl-
ation with hypertriglyceridemia independent of age, gen-
der and pubertal status, but it was not in statistically
significant association with hypertension. This is the first
study in obese children concerning IGF-1 and metabolic
syndrome and its components.
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The positive association between low IGF-1 with a low
level of HDL-C and metabolic syndrome observed in
this study suggests that a low IGF-1 level contributes to
the increased risk of cardiovascular disease in obese chil-
dren and adolescents, implying that IGF-1 may be an
important biomarker for clinicians to identify subjects at
risk for early cardiovascular disease in obese children.
Further research in prospective studies is needed to bet-
ter understand these relationships.
The present study has several strengths and fills some
research gaps. First, to the best of our knowledge, our
study is one of the first to focus on the relationship be-
tween circulating IGF-1 levels and serum HDL-C based
on a dataset of obese children individuals independent of
several confounding factors. Second, several confounding
variables had been reported to affect IGF-1 levels. In the
current study, in order to limit the confounding effects of
age and sex, we used the IGF-1 SDS as a proxy of IGF-1.
The standardized IGF-1 levels have not been applied in
previous studies regarding the relationship between IGF-1
and HDL-C. Third, our study included the relatively large
sample size with detailed clinical characterization.
However, our study has some potential limitations.
The first limitation is the cross sectional design of this
study doesn’t not allow us to determine causality. Sec-
ondly, we did not analyze GH, IGF binding proteins
(IGFBPs) and free IGF-1. Thirdly, serum HDL-C and
IGF-1 were measured without replication.
Conclusion
In conclusion, our results suggest that, obese children
and adolescents had lower IGF-1SDS and taller stature
compared with the control group. There is an independ-
ent association among lower IGF-1, low HDL-C and meta-
bolic syndrome. Thus, the inclusion of measurement of
IGF-1 and HDL-C levels might be warranted in the assess-
ment protocols for obese or overweight children and ado-
lescents, in order to verify possible complications of early
cardiovascular alterations. Also developing a new preven-
tion and treatment strategies for increasing serum IGF-1
levels would benefit in controling low HDL-C and meta-
bolic syndrome.
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